Based solely on their expression levels, it can be considered that Abs targeting FcRH5 might be more effective against CD34+ MM cells compared to CD34− MM cells, while those targeting GPRC5D might be less effective for this cell population. This evidence concerns the gene CD34 and Miyoshi myopathy.